Trial Profile
Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 06 Nov 2008 New trial record.